Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of a shiny sun and deliciously cool breeze wafting through the serene Pharmalot campus. Our short person has left for the schoolhouse, our official mascot is slumbering at our feet, and our coffee kettle is whistling a familiar tune. All that needs to be done is to now dig in for another busy day. On that note, here are a few items of interest. Hope you conquer the world today and, as always, drop us a line if you run across something saucy or fascinating …

After years of frustration, Vertex Pharmaceuticals (VRTX) struck a deal with the U.K. government to supply its cystic fibrosis medicines, capping an end to a dispute that had become a symbol of the growing clash between cash-strapped governments and drug makers over the rising prices for medicines, STAT reports. The agreement covers all cystic fibrosis treatments sold by Vertex, including a new triple-combination therapy once it is licensed in the U.K., although pricing was not disclosed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!